Stem Genomics

Executive Summary

Stem Genomics, a French biotechnology spin-out from the Institute for Regenerative Medicine & Biotherapy (IRMB) founded in 2018, provides genetic stability testing and quality control services for stem cell research and cell therapy development. Its comprehensive suite includes digital karyotyping, cell authentication, mycoplasma detection, and pluripotency testing, all designed to comply with ISSCR standards. By targeting scientists working with human pluripotent stem cells (hPSCs), mesenchymal stromal cells (MSCs), and other cell types, the company addresses a critical need for genomic integrity assurance in both research and clinical applications. With the global stem cell market expanding rapidly due to advances in regenerative medicine, Stem Genomics is positioned to capture demand from academic institutions, biotechs, and pharmaceutical companies seeking reliable quality control solutions.

Upcoming Catalysts (preview)

• Q3 2026Launch of new multi-parameter genomic stability panel60% success
• Q4 2026Partnership with a major cell therapy developer for quality control services40% success
• Q2 2026Publication of validation data supporting new assay in peer-reviewed journal70% success